



## Clinical trial results:

### Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route)

#### Summary

EudraCT number	2009-017688-40
Trial protocol	BE
Global end of trial date	24 June 2010

#### Results information

Result version number	v1 (current)
This version publication date	05 February 2016
First version publication date	29 January 2015

#### Trial information

##### Trial identification

Sponsor protocol code	GID34
-----------------------	-------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01138397
WHO universal trial number (UTN)	U1111-1112-2795

Notes:

#### Sponsors

Sponsor organisation name	Sanofi Pasteur SA
Sponsor organisation address	2, Avenue Pont Pasteur, Lyon cedex 07, France, F-69367
Public contact	Director, Clinical Development, Sanofi Pasteur SA, 33 4 37 37 58 50, Stephanie.pepin@sanofipasteur.com
Scientific contact	Director, Clinical Development, Sanofi Pasteur SA, 33 4 37 37 58 50, Stephanie.pepin@sanofipasteur.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	07 July 2010
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	24 June 2010
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

In each group:

- 1) To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the ID influenza vaccine Northern Hemisphere (NH) 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96
- 2) To describe the safety of the corresponding strength of the ID influenza vaccine, NH 2010-2011 formulation

Protection of trial subjects:

Only subjects who met all the study inclusion and none of the exclusion criteria were vaccinated in the study. Vaccinations were performed by qualified and trained study personnel. Subjects with allergy to any of the vaccine components were not vaccinated. After vaccination, subjects were also kept under clinical observation for 30 minutes to ensure their safety. Appropriate medical equipment was also available on site in case of any immediate allergic reactions.

Background therapy:

Not applicable

Evidence for comparator:

Not applicable

Actual start date of recruitment	02 June 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 130
Worldwide total number of subjects	130
EEA total number of subjects	130

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	78
From 65 to 84 years	52
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Study subjects were enrolled from 02 June 2010 to 03 June 2010 in 2 clinical centers in Belgium.

### Pre-assignment

Screening details:

A total of 130 subjects who met all the inclusion criteria and none of the exclusion criteria were enrolled, 129 were vaccinated.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not applicable

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	18 to 59 years; ID 9µg

Arm description:

Adults aged 18 to 59 years who received the intradermal (ID) influenza vaccine 9µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.

Arm type	Experimental
Investigational medicinal product name	Influenza vaccine (split-virion, inactivated) for intradermal route, NH 2010-2011
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intradermal use

Dosage and administration details:

0.1 mL dose (9µg strength), intradermal (ID) in the region of the deltoid muscle, one dose on Day 0.

<b>Arm title</b>	60 years or older; ID 15µg
------------------	----------------------------

Arm description:

Adults aged 60 years or older who received the intradermal (ID) influenza vaccine 15µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.

Arm type	Experimental
Investigational medicinal product name	Influenza vaccine (split-virion, inactivated) for intradermal route, NH 2010-2011
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intradermal use

Dosage and administration details:

0.1 mL dose (15µg strength), intradermal (ID) in the region of the deltoid muscle, one dose on Day 0.

<b>Number of subjects in period 1</b>	18 to 59 years; ID 9µg	60 years or older; ID 15µg
Started	65	65
Completed	64	65
Not completed	1	0
Protocol deviation	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	18 to 59 years; ID 9µg
Reporting group description: Adults aged 18 to 59 years who received the intradermal (ID) influenza vaccine 9µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.	
Reporting group title	60 years or older; ID 15µg
Reporting group description: Adults aged 60 years or older who received the intradermal (ID) influenza vaccine 15µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.	

Reporting group values	18 to 59 years; ID 9µg	60 years or older; ID 15µg	Total
Number of subjects	65	65	130
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	65	13	78
From 65-84 years	0	52	52
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	34.2	68.8	-
standard deviation	± 13.2	± 5	-
Gender categorical Units: Subjects			
Female	37	29	66
Male	28	36	64
Previous seasonal influenza vaccination Units: Subjects			
Yes	21	52	73
No	44	13	57
Unknown	0	0	0

## End points

### End points reporting groups

Reporting group title	18 to 59 years; ID 9µg
Reporting group description: Adults aged 18 to 59 years who received the intradermal (ID) influenza vaccine 9µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.	
Reporting group title	60 years or older; ID 15µg
Reporting group description: Adults aged 60 years or older who received the intradermal (ID) influenza vaccine 15µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.	

### Primary: Geometric Mean Titers (GMTs) of Influenza Antibodies Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route

End point title	Geometric Mean Titers (GMTs) of Influenza Antibodies Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[1]</sup>
End point description: Immunogenicity was evaluated using the hemagglutination inhibition (HAI) method.	
End point type	Primary
End point timeframe: Day 0 (pre-vaccination) and Day 21 post-vaccination	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9µg	60 years or older; ID 15µg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	65		
Units: Titer (1/dil)				
geometric mean (confidence interval 95%)				
A/California/7/2009 (H1N1) like strain; D0	18.5 (12.4 to 27.5)	9.48 (7.3 to 12.3)		
A/California/7/2009 (H1N1) like strain; D21	900 (639 to 1268)	138 (90.4 to 210)		
A/Perth/16/2009 (H3N2) like strain; D0	31.3 (22.4 to 43.7)	29.8 (20.9 to 42.6)		
A/Perth/16/2009 (H3N2) like strain; D21	1223 (907 to 1650)	394 (275 to 564)		
Whole B/Brisbane/60/2008 like strain; D0	13.1 (9.49 to 18.2)	13.9 (10.7 to 18.1)		
Whole B/Brisbane/60/2008 like strain; D21	176 (134 to 231)	42.6 (31.3 to 58.1)		
Split B/Brisbane/60/2008 like strain; D0	29.6 (20 to 43.9)	47.4 (33 to 68.1)		
Split B/Brisbane/60/2008 like strain; D21	644 (490 to 846)	193 (143 to 259)		

## Statistical analyses

No statistical analyses for this end point

### **Primary: Percentage of Subjects With Seroprotection Against Influenza Antigens Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route**

End point title	Percentage of Subjects With Seroprotection Against Influenza Antigens Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[2]</sup>
-----------------	---

End point description:

Immunogenicity was evaluated using the hemagglutination inhibition (HAI) method. Seroprotection was defined as a titer  $\geq 40$  (1/dilution [1/dil]) on Day 0 and Day 21.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 (pre-vaccination) and Day 21 post-vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9 $\mu$ g	60 years or older; ID 15 $\mu$ g		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	65		
Units: Percentage of subjects				
number (not applicable)				
A/California/7/2009 (H1N1) like strain; D0	31.1	12.3		
A/California/7/2009 (H1N1) like strain; D21	98.4	76.9		
A/Perth/16/2009 (H3N2) like strain; D0	49.2	47.7		
A/Perth/16/2009 (H3N2) like strain; D21	100	93.8		
Whole B/Brisbane/60/2008 like strain; D0	24.6	27.7		
Whole B/Brisbane/60/2008 like strain; D21	96.7	56.9		
Split B/Brisbane/60/2008 like strain; D0	36.1	58.5		
Split B/Brisbane/60/2008 like strain; D21	98.4	93.8		

## Statistical analyses

No statistical analyses for this end point



**Primary: Percentage of Subjects With Influenza Antibodies Titers < 10 1/dil Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route**

End point title	Percentage of Subjects With Influenza Antibodies Titers < 10 1/dil Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[3]</sup>
-----------------	--

End point description:

Immunogenicity was evaluated using the hemagglutination inhibition (HAI) method.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 (pre-vaccination) and Day 21 post-vaccination

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9µg	60 years or older; ID 15µg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	65		
Units: Percentage of subjects				
number (not applicable)				
A/California/7/2009 (H1N1) like strain; D0	42.6	60		
A/California/7/2009 (H1N1) like strain; D21	0	1.5		
A/Perth/16/2009 (H3N2) like strain; D0	16.4	26.2		
A/Perth/16/2009 (H3N2) like strain; D21	0	0		
Whole B/Brisbane/60/2008 like strain; D0	52.5	40		
Whole B/Brisbane/60/2008 like strain; D21	1.6	10.8		
Split B/Brisbane/60/2008 like strain; D0	29.5	15.4		
Split B/Brisbane/60/2008 like strain; D21	0	0		

**Statistical analyses**

No statistical analyses for this end point

**Primary: Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route**

End point title	Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[4]</sup>
-----------------	---

End point description:

Immunogenicity was evaluated using the hemagglutination inhibition (HAI) method. Geometric mean of individual ratio was defined as the mean geometric increase between Day 0 and Day 21 as per the CPMP NfG.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 (pre-vaccination) and Day 21 post-vaccination

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9µg	60 years or older; ID 15µg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	65		
Units: Titer (1/dil)				
geometric mean (confidence interval 95%)				
A/California/7/2009 (H1N1) like strain	48.7 (33.4 to 71.1)	14.5 (9.96 to 21.2)		
A/Perth/16/2009 (H3N2) like strain	39 (26.3 to 58)	13.2 (8.96 to 19.5)		
Whole B/Brisbane/60/2008 like strain	13.4 (8.87 to 20.3)	3.06 (2.27 to 4.13)		
Split B/Brisbane/60/2008 like strain	21.7 (14 to 33.7)	4.06 (2.87 to 5.77)		

## Statistical analyses

No statistical analyses for this end point

### **Primary: Percentage of Subjects Achieving Seroconversion or Significant increase Against Influenza Antigen Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route**

End point title	Percentage of Subjects Achieving Seroconversion or Significant increase Against Influenza Antigen Before and After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[5]</sup>
-----------------	---

End point description:

Immunogenicity was evaluated using the hemagglutination inhibition (HAI) method. Seroconversion was defined as subjects with a titer <10 (1/dil) on Day 0: post-injection titer ≥40 (1/dil) on Day 21 or significant increase for subjects with a titer ≥10 (1/dil) on Day 0: ≥4-fold increase of post-injection titer on Day 21.

End point type	Primary
----------------	---------

End point timeframe:

Day 21 post-vaccination

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9µg	60 years or older; ID 15µg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	65		
Units: Percentage of subjects				
number (not applicable)				
A/California/7/2009 (H1N1) like strain	93.4	70.8		
A/Perth/16/2009 (H3N2) like strain	95.1	81.5		
Whole B/Brisbane/60/2008 like strain	75.4	26.2		
Split B/Brisbane/60/2008 like strain	77	43.1		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Solicited Reactions Listed in the CPMP Note for Guidance Within 3 Days After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route

End point title	Percentage of Subjects Reporting Solicited Reactions Listed in the CPMP Note for Guidance Within 3 Days After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[6]</sup>
-----------------	--

End point description:

Solicited injection site reactions: Injection site induration ≥5 cm for at least 4 consecutive days and Injection site ecchymosis. Solicited systemic reactions: Pyrexia (recorded temperature >38°C) for at least 1 day, Malaise, and Shivering.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 up to Day 3 post-vaccination

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9µg	60 years or older; ID 15µg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Percentage of subjects				
number (not applicable)				
At least 1 reaction listed in EMEA recommendation	20.6	23.1		
Injection site Induration ≥5 cm for ≥ 4 days	0	0		
Injection site Ecchymosis	1.6	3.1		
Pyrexia (recorded temp. >38°C) for at least 1 day	3.2	1.5		
Malaise	15.9	20		
Shivering	3.2	4.6		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Solicited Injection-site or Systemic Reaction Within 3 Days After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route

End point title	Percentage of Subjects Reporting Solicited Injection-site or Systemic Reaction Within 3 Days After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[7]</sup>
-----------------	---

End point description:

Solicited injection site: Pain, Pruritus, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 Solicited Injection site reactions: Pain and Pruritus – Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis - >10 cm. Grade 3 Solicited systemic reactions: Fever -  $\geq 39^{\circ}\text{C}$ ; Headache, Malaise, Myalgia, and Shivering – Significant, prevents daily activity.

End point type	Primary
----------------	---------

End point timeframe:

Day 0 up to Day 3 post-vaccination

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9 $\mu\text{g}$	60 years or older; ID 15 $\mu\text{g}$		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Percentage of subjects number (not applicable)				
Injection site Pain	57.1	26.2		
Grade 3 Injection site Pain	0	0		
Injection site Pruritus	34.9	27.7		
Grade 3 Injection site Pruritus	0	0		
Injection site Erythema	65.1	50.8		
Grade 3 Injection site Erythema	0	0		
Injection site Swelling	20.6	15.4		
Grade 3 Injection site Swelling	0	0		
Injection site Induration	17.5	13.8		
Grade 3 Injection site Induration	0	0		
Injection site Ecchymosis	0	0		
Grade 3 Injection site Ecchymosis	0	0		
Fever	3.2	1.5		
Grade 3 Fever	1.6	0		
Headache	25.4	12.3		

Grade 3 Headache	4.8	0		
Malaise	15.9	20		
Grade 3 Malaise	1.6	0		
Myalgia	4.8	6.2		
Grade 3 Myalgia	0	0		
Shivering	3.2	4.6		
Grade 3 Shivering	0	0		

## Statistical analyses

No statistical analyses for this end point

### Primary: Percentage of Subjects Reporting Solicited Injection-site or Systemic Reaction More than 3 Days After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route

End point title	Percentage of Subjects Reporting Solicited Injection-site or Systemic Reaction More than 3 Days After Vaccination with Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation Administered by Intradermal Route <sup>[8]</sup>
-----------------	--

End point description:

Solicited injection site: Pain, Pruritus, Erythema, Swelling, Induration and Ecchymosis. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Shivering. Grade 3 Solicited Injection site reactions: Pain and Pruritus – Significant, prevents daily activity; Erythema, Swelling, Induration, and Ecchymosis - >10 cm. Grade 3 Solicited systemic reactions: Fever -  $\geq 39^{\circ}\text{C}$ ; Headache, Malaise, Myalgia, and Shivering – Significant, prevents daily activity.

End point type	Primary
----------------	---------

End point timeframe:

>Day 3 post-vaccination

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive analyses were performed based on the study groups and the study vaccine administered for this outcome.

End point values	18 to 59 years; ID 9 $\mu\text{g}$	60 years or older; ID 15 $\mu\text{g}$		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	63	65		
Units: Percentage of subjects				
number (not applicable)				
Injection site Pain	0	0		
Grade 3 Injection site Pain	0	0		
Injection site Pruritus	3.2	0		
Grade 3 Injection site Pruritus	0	0		
Injection site Erythema	1.6	0		
Grade 3 Injection site Erythema	0	0		
Injection site Swelling	0	0		
Grade 3 Injection site Swelling	0	0		
Injection site Induration	0	0		
Grade 3 Injection site Induration	0	0		
Injection site Ecchymosis	0	0		

Grade 3 Injection site Ecchymosis	0	0		
Fever	0	0		
Grade 3 Fever	0	0		
Headache	7.9	0		
Grade 3 Headache	0	0		
Malaise	3.2	1.5		
Grade 3 Malaise	0	0		
Myalgia	3.2	0		
Grade 3 Myalgia	0	0		
Shivering	3.2	1.5		
Grade 3 Shivering	0	0		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse event data were collected from Day 0 (post-vaccination) up to Day 21 post-vaccination.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.0
--------------------	------

### Reporting groups

Reporting group title	18 to 59 years; ID 9µg
-----------------------	------------------------

Reporting group description:

Adults aged 18 to 59 years who received the intradermal (ID) influenza vaccine 9µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.

Reporting group title	60 years or older; ID 15µg
-----------------------	----------------------------

Reporting group description:

Adults aged 60 years or older who received the intradermal (ID) influenza vaccine 15µg Northern Hemisphere (NH) 2010-2011 formulation on Day 0.

Serious adverse events	18 to 59 years; ID 9µg	60 years or older; ID 15µg	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 63 (0.00%)	0 / 65 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	18 to 59 years; ID 9µg	60 years or older; ID 15µg	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	41 / 63 (65.08%)	33 / 65 (50.77%)	
Nervous system disorders			
Headache			
alternative assessment type: Systematic			
subjects affected / exposed	16 / 63 (25.40%)	8 / 65 (12.31%)	
occurrences (all)	16	8	
General disorders and administration site conditions			
Injection site pain			
alternative assessment type: Systematic			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>36 / 63 (57.14%)</p> <p>36</p>	<p>17 / 65 (26.15%)</p> <p>17</p>	
<p>Injection site erythema</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>41 / 63 (65.08%)</p> <p>41</p>	<p>33 / 65 (50.77%)</p> <p>33</p>	
<p>Injection site swelling</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>13 / 63 (20.63%)</p> <p>13</p>	<p>10 / 65 (15.38%)</p> <p>10</p>	
<p>Malaise</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>10 / 63 (15.87%)</p> <p>10</p>	<p>13 / 65 (20.00%)</p> <p>13</p>	
<p>Skin and subcutaneous tissue disorders</p> <p>Injection site induration</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>11 / 63 (17.46%)</p> <p>11</p>	<p>9 / 65 (13.85%)</p> <p>9</p>	
<p>Musculoskeletal and connective tissue disorders</p> <p>Myalgia</p> <p>alternative assessment type: Systematic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>3 / 63 (4.76%)</p> <p>3</p>	<p>4 / 65 (6.15%)</p> <p>4</p>	



## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported